Literature DB >> 12727693

Decreased striatal dopamine D1 receptor-stimulated adenylyl cyclase activity in human methamphetamine users.

Junchao Tong1, Brian M Ross, Gregory A Schmunk, Frank J Peretti, Kathryn S Kalasinsky, Yoshiaki Furukawa, Lee Cyn Ang, Sally S Aiken, Dennis J Wickham, Stephen J Kish.   

Abstract

OBJECTIVE: It has been assumed that some behavioral changes associated with repeated exposure to dopaminergic psychostimulant drugs might be explained by changes in activity of dopamine receptors, including the dopamine D(1) receptor, which is linked by a stimulatory G protein to the effector enzyme adenylyl cyclase. To establish whether dopamine D(1) receptor function might be altered in human methamphetamine users, the authors measured dopamine-stimulated adenylyl cyclase activity in the brain of chronic human users of the drug.
METHOD: Adenylyl cyclase activity stimulated by dopamine and by guanylyl-imidodiphosphate (to assess G protein and adenylyl cyclase coupling) was determined in the postmortem brain tissue of 16 methamphetamine users who had used the drug both recently and chronically (i.e., at least 1 year) as well as 21 matched comparison subjects.
RESULTS: A 25%-30% decrease in the maximal extent of dopamine stimulation of adenylyl cyclase activity was seen in the striatum (nucleus accumbens, caudate, and putamen) of the methamphetamine users. No changes were found in basal or guanylyl-imidodiphosphate-stimulated enzyme activity.
CONCLUSIONS: These data suggest that dopamine receptor function linked to adenylyl cyclase is partially desensitized in the striatum of human methamphetamine users. Decreased dopamine D(1) receptor function might underlie part of the known (drug withdrawal syndrome) or expected (drug tolerance) consequences of methamphetamine exposure in humans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12727693     DOI: 10.1176/appi.ajp.160.5.896

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  10 in total

1.  Prolonged exposure of rats to intravenous methamphetamine: behavioral and neurochemical characterization.

Authors:  David S Segal; Ronald Kuczenski; Meghan L O'Neil; William P Melega; Arthur K Cho
Journal:  Psychopharmacology (Berl)       Date:  2005-03-15       Impact factor: 4.530

2.  Long-term upregulation of protein kinase A and adenylate cyclase levels in human smokers.

Authors:  Bruce T Hope; Deepti Nagarkar; Sherry Leonard; Roy A Wise
Journal:  J Neurosci       Date:  2007-02-21       Impact factor: 6.167

3.  Neonatal +-methamphetamine exposure in rats alters adult locomotor responses to dopamine D1 and D2 agonists and to a glutamate NMDA receptor antagonist, but not to serotonin agonists.

Authors:  Devon L Graham; Robyn M Amos-Kroohs; Amanda A Braun; Curtis E Grace; Tori L Schaefer; Matthew R Skelton; Michael T Williams; Charles V Vorhees
Journal:  Int J Neuropsychopharmacol       Date:  2012-03-06       Impact factor: 5.176

Review 4.  Activators of G-protein signaling 3: a drug addiction molecular gateway.

Authors:  Michael Scott Bowers
Journal:  Behav Pharmacol       Date:  2010-09       Impact factor: 2.293

5.  Brain serotonin transporter in human methamphetamine users.

Authors:  Stephen J Kish; Paul S Fitzmaurice; Isabelle Boileau; Gregory A Schmunk; Lee-Cyn Ang; Yoshiaki Furukawa; Li-Jan Chang; Dennis J Wickham; Allan Sherwin; Junchao Tong
Journal:  Psychopharmacology (Berl)       Date:  2008-10-08       Impact factor: 4.530

Review 6.  Animal models and treatments for addiction and depression co-morbidity.

Authors:  Neil E Paterson; Athina Markou
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

7.  Treatment of methamphetamine-induced psychosis: a double-blind randomized controlled trial comparing haloperidol and quetiapine.

Authors:  Viroj Verachai; Warangkana Rukngan; Kachornwan Chawanakrasaesin; Sumnao Nilaban; Somporn Suwanmajo; Rossukon Thanateerabunjong; Jaranit Kaewkungwal; Rasmon Kalayasiri
Journal:  Psychopharmacology (Berl)       Date:  2014-02-18       Impact factor: 4.530

Review 8.  Psychostimulants, madness, memory... and RGS proteins?

Authors:  Scott A Burchett
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 4.103

9.  Decreased dopamine activity predicts relapse in methamphetamine abusers.

Authors:  G J Wang; L Smith; N D Volkow; F Telang; J Logan; D Tomasi; C T Wong; W Hoffman; M Jayne; N Alia-Klein; P Thanos; J S Fowler
Journal:  Mol Psychiatry       Date:  2011-07-12       Impact factor: 15.992

10.  Striatal dopamine D1-type receptor availability: no difference from control but association with cortical thickness in methamphetamine users.

Authors:  K Okita; A M Morales; A C Dean; M C Johnson; V Lu; J Farahi; M A Mandelkern; E D London
Journal:  Mol Psychiatry       Date:  2017-09-12       Impact factor: 15.992

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.